Reparixin

Catalog No: 25050

CAS Number: 266359-83-5

Purity: 98% Min.

Reparixin is an inhibitor of CXCR2 function, which attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord. In a human breast cancer cell line, both reparixin reduced the number of breast cancer stem cells compared with no treatment. I n mice with primary human breast cancer xenografts, reparixin alone or in combination with docetaxel reduced tumor growth compared with saline control. The combination had greater efficacy than either reparixin or docetaxel alone.

For research use only. We do not sell to patients.

Chemical Information

Name	Reparixin
Iupac Chemical Name	(R)-2-(4-isobutylphenyl)-N-(methylsulfonyl)propanamide
Synonyms	DF 1681Y; DF-1681Y; DF1681Y; Reparixin; Repertaxin.
Molecular Formula	C14H21NO3S
Molecular Weight	283.39
Smile	C[C@H](C1=CC=C(CC(C)C)C=C1)C(NS(=O)(C)=O)=O
InChiKey	KQDRVXQXKZXMHP-LLVKDONJSA-N
InChi	InChI=1S/C14H21NO3S/c1-10(2)9-12-5-7-13(8-6-12)11(3)14(16)15-19(4,17)18/h5-8,10-11H,9H2,1-4H3,(H,15,16)/t11-/m1/s1
CAS Number	266359-83-5
Related CAS

Ordering Information

Packaging	Price	Availability	Purity	Shipping Time
Bulk		Enquiry	Enquiry	Enquiry

Request Bulk Quote Download MSDS Tel : +86-177 0271 9238 Email : sales@sun-shinechem.com

Formulation	Off-white solid
Purity	98% Min.
Storage	Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years).
Solubility	Soluble in DMSO
Handling
Shipping Condition	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
HS Code

Coming soon.

Targets
Mechanism
Cell study
Animal study
Clinical study

1: Kim HY, Choi JH, Kang YJ, Park SY, Choi HC, Kim HS. Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats. Biol Pharm Bull. 2011;34(1):120-7. PubMed PMID: 21212529.

2: Zarbock A, Allegretti M, Ley K. Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice. Br J Pharmacol. 2008 Oct;155(3):357-64. doi: 10.1038/bjp.2008.270. Epub 2008 Jun 30. PubMed PMID: 18587419; PubMed Central PMCID: PMC2567887.

3: Gorio A, Madaschi L, Zadra G, Marfia G, Cavalieri B, Bertini R, Di Giulio AM. Reparixin, an inhibitor of CXCR2 function, attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord. J Pharmacol Exp Ther. 2007 Sep;322(3):973-81. Epub 2007 Jun 29. PubMed PMID: 17601981.

4: Villa P, Triulzi S, Cavalieri B, Di Bitondo R, Bertini R, Barbera S, Bigini P, Mennini T, Gelosa P, Tremoli E, Sironi L, Ghezzi P. The interleukin-8 (IL-8/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats. Mol Med. 2007 Mar-Apr;13(3-4):125-33. PubMed PMID: 17592546; PubMed Central PMCID: PMC1892761.

5: Leitner JM, Mayr FB, Firbas C, Spiel AO, Steinlechner B, Novellini R, Jilma B. Reparixin, a specific interleukin-8 inhibitor, has no effects on inflammation during endotoxemia. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):25-36. PubMed PMID: 17346425.

6: Midgley I, Fitzpatrick K, Wright SJ, John BA, Peard AJ, Major RM, Holding JD, McBurney A, Anacardio R, Novellini R, Ferrari MP. Species differences in the pharmacokinetics and metabolism of reparixin in rat and dog. Xenobiotica. 2006 May;36(5):419-40. PubMed PMID: 16854780.

Chemical Structure

Reparixin

Chemical Information

Ordering Information

Chemical Structure

Quick Order

Products